Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 2/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8384245 | 1.00 | MTNR1A (0.60) | MTNR1AMTNR1BNPC1RAB9ATAAR1 | |
| SCHEMBL8384291 | 1.00 | MTNR1A (0.60) | MTNR1AMTNR1BNPC1RAB9ATAAR1 | |
| SCHEMBL28904956 | 0.95 | MTNR1A (0.55) | MTNR1AMTNR1BNPC1RAB9ATAAR1 | |
| SCHEMBL4530460 | 0.86 | NPC1 (0.61) | NPC1RAB9ATAAR1AOC3TP53 | |
| Hydrochloric Acid SCHEMBL4323386 | 0.85 | TAAR1 (0.60) | NPC1RAB9ATAAR1AOC3TP53 | |
| SCHEMBL2091812 | 0.84 | MTNR1A (0.67) | MTNR1AMTNR1BNPC1RAB9AAPAF1 | |
| SCHEMBL8499532 | 0.83 | NPC1 (0.58) | NPC1RAB9ATAAR1AOC3TP53 | |
| SCHEMBL2432247 | 0.83 | BCAT2 (0.66) | NPC1RAB9ATAAR1AOC3TP53 | |
| SCHEMBL7909475 | 0.83 | NPC1 (0.58) | NPC1RAB9ATAAR1AOC3TP53 | |
| SCHEMBL12862954 | 0.83 | NPC1 (0.58) | NPC1RAB9ATAAR1AOC3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942499-B | Quinazoline derivative and preparation method and application thereof | 湖南中医药大学 | 2022-03-22 | — | — | CN | disclosed |
| EP-3364940-B1 | METHOD OF CHROMATOGRAPHIC SEPARATION | PROCTER & GAMBLE (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-109942499-A | Quinazoline derivant and its preparation method and application | 湖南中医药大学 | 2019-06-28 | — | — | CN | disclosed |
| US-10035759-B2 | Method of chromatographic separation | THE PROCTER & GAMBLE COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017070414-A1 | METHOD OF CHROMATOGRAPHIC SEPARATION | THE PROCTER & GAMBLE COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-2616469-B1 | 9H-PURINE COMPOUNDS AS PI3K-DELTA INHIBITORS AND METHODS FOR THEIR MANUFACTURE | EXELIXIS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| CN-105859783-A | Novel chiral phosphine ligand, metal catalyst containing chiral phosphine ligand and preparation method and application thereof | 宁波赜军医药科技有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | JANSSENS FRANS EDUARD | 2008-03-20 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| CN-1182837-C | Orally administrable immediate and prolonged-release Galenic form comprising absorption-promoting agent and use of this absorption-promoting agent | Ĭ��ר���ɷ�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MTNR1A 427/4885MTNR1B 461/4885NPC1 715/4885 |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | MTNR1A 182/4885MTNR1B 165/4885NPC1 880/4885 |
| US-20080070924-A1 | Novel Formulations For Opioid-Based Treatments Of Pain Comprising 1-(1,2-Disubstituted Piperidinyl)-4-Substituted Piperazine Derivatives | OPRL1, OPRK1, OPRM1 | MTNR1A 91/4885MTNR1B 122/4885NPC1 1524/4885 |
| US-10035759-B2 | Method of chromatographic separation | AVPR2, SHBG, AVPR1B | MTNR1A 1094/4885MTNR1B 315/4885NPC1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.